NCT00398541已完成3 期
Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 41
- 主要终点
- Neuropsychological tests and blood pressure after treatment of 12 weeks
研究概览
简要总结
Evaluate the antihypertensive and neuroprotective effects of Hyzaar(R) in elderly subjects in comparison with Natrilix(TM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ACEi or ARB naive or not taking ACEi or ARB concurrently for at least one month before the run-in period
- •Be able to carry out his or her own daily activity
- •- Be at least 50 years old at inclusion in the study Be diagnosed with mild to moderate hypertension, treated or untreated
- •Not taking any cognitive-enhanced agent at baseline
- •Present with a memory complain ( spontaneous or informed by caregiver)
排除标准
- •Congestive heart failure with NYHA class >2
- •Renal failure or renal insufficiency with serum creatinine >1.4mg/dl
- •chronic severe liver disease with abnormal GPT and GOT >2 times of upper normal limits
- •Diagnosed with major depression when entering the study
- •Foreign language as his or her mother tongue so that the test results will not be reliable
- •History of stroke or transient ischemic attack (stroke is defined as focal neurological sign progressing stepwise)
- •Hypersensitive to the active ingredient and any other component of losartan potassium and indapamide tablets
- •Major hearing loss/deafness and/or major visual impairment/blindness preventing from performing the tests
- •Myocardial infarction within the past 6 months
- •Single functioning kidney
结局指标
主要结局
Neuropsychological tests and blood pressure after treatment of 12 weeks
时间窗: after treatment of 12 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)HypertensionNCT00400218Organon and Co62
已完成
不适用
Potency of antihypertensive therapy with Azilsartan on Walking Activity among Peripheral Artery Disease Patients With hypertention and Intermittent ClaudicatioPeripheral artery diseaseJPRN-UMIN000013670Sakakibara heart Institute14
已完成
3 期
Systolic Hypertension in the Elderly Program (SHEP)Heart DiseasesCardiovascular DiseasesCerebrovascular DisordersHypertensionNCT00000514National Heart, Lung, and Blood Institute (NHLBI)
进行中（未招募）
1 期
HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy - HYPAZ: Hypertension induced by pazopanibHypertension induced by pazopanib treatment of various cancer typesMedDRA version: 16.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021613-23-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge27
Unknown
不适用
Exploring the Effect of Combined Chinese and Western Treatment on Home Medical CareHypertensionNCT03600220Taipei City Hospital80